CD274 and neoplasm: BMS‐202 is a small‐molecule PD‐L1 inhibitor that disrupts the PD‐L1 dimerization, which exhibited several advantages over the traditional antibody‐based checkpoint inhibitor, such as higher stability, improved tumor penetration, lower immunogenicity, and facile production process.